glp-1 receptor agonist antipsychotic weight gain study and Metabolic Syndrome (MetS) Battle of the Bulge: Obesity

The case report indicates that no abnormalities were identified in the medical evaluations and symptoms only resolved after stopping the use of semaglutide

Ongoing concerns associated with GLP-1 RA use are the potential for weight gain after stopping treatment and long-term adherence due to AEsalthough the investigators noted that the most common GI AEs tend to diminish with longer use and are more pronounced during initial treatment

The FDA has classified osteoarthritis as a serious disease with no disease-modifying treatments available

Activation of the GLP-1 receptor signalling pathway: A relevant strategy to repair a deficient beta-cell mass

[DOI] [PubMed] [Google Scholar] 711.Kohno D., Sone H., Tanaka S., Kurita H., Gantulga D., Yada T

Even though extensive research conducted over the last years did not unequivocally establish the etiology of depression, it revealed the complexity of its pathogenesis